Updated Cures 2.0 Directs FDA To Spur Use Of Decentralized Clinical Trials

An updated version of Cures 2.0, a major FDA reform bill spearheaded by Reps. Diana DeGette (D-CO) and Fred Upton (R-MI), includes a new provision calling on FDA to take steps to rely more on decentralized clinical trials. Aside from the new decentralized clinical trials stipulation, the bill maintains nearly all the FDA reforms included in the draft version released in June. The updated bill directs the FDA commissioner to, by the end of fiscal 2022, bring together clinical research...